240 related articles for article (PubMed ID: 9254653)
1. Degradation of mouse invariant chain: roles of cathepsins S and D and the influence of major histocompatibility complex polymorphism.
Villadangos JA; Riese RJ; Peters C; Chapman HA; Ploegh HL
J Exp Med; 1997 Aug; 186(4):549-60. PubMed ID: 9254653
[TBL] [Abstract][Full Text] [Related]
2. Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages.
Shi GP; Bryant RA; Riese R; Verhelst S; Driessen C; Li Z; Bromme D; Ploegh HL; Chapman HA
J Exp Med; 2000 Apr; 191(7):1177-86. PubMed ID: 10748235
[TBL] [Abstract][Full Text] [Related]
3. Invariant chain processing is independent of cathepsin variation between primary human B cells/dendritic cells and B-lymphoblastoid cells.
Reich M; Zou F; Sieńczyk M; Oleksyszyn J; Boehm BO; Burster T
Cell Immunol; 2011; 269(2):96-103. PubMed ID: 21543057
[TBL] [Abstract][Full Text] [Related]
4. Both cathepsin B and cathepsin D are necessary for processing of ovalbumin as well as for degradation of class II MHC invariant chain.
Mizuochi T; Yee ST; Kasai M; Kakiuchi T; Muno D; Kominami E
Immunol Lett; 1994 Dec; 43(3):189-93. PubMed ID: 7721331
[TBL] [Abstract][Full Text] [Related]
5. Cathepsin S controls MHC class II-mediated antigen presentation by epithelial cells in vivo.
Beers C; Burich A; Kleijmeer MJ; Griffith JM; Wong P; Rudensky AY
J Immunol; 2005 Feb; 174(3):1205-12. PubMed ID: 15661874
[TBL] [Abstract][Full Text] [Related]
6. Cathepsin S activity regulates antigen presentation and immunity.
Riese RJ; Mitchell RN; Villadangos JA; Shi GP; Palmer JT; Karp ER; De Sanctis GT; Ploegh HL; Chapman HA
J Clin Invest; 1998 Jun; 101(11):2351-63. PubMed ID: 9616206
[TBL] [Abstract][Full Text] [Related]
7. A role for cathepsin L and cathepsin S in peptide generation for MHC class II presentation.
Hsieh CS; deRoos P; Honey K; Beers C; Rudensky AY
J Immunol; 2002 Mar; 168(6):2618-25. PubMed ID: 11884425
[TBL] [Abstract][Full Text] [Related]
8. Major histocompatibility complex class II-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin L.
Bevec T; Stoka V; Pungercic G; Dolenc I; Turk V
J Exp Med; 1996 Apr; 183(4):1331-8. PubMed ID: 8666891
[TBL] [Abstract][Full Text] [Related]
9. Cathepsin S required for normal MHC class II peptide loading and germinal center development.
Shi GP; Villadangos JA; Dranoff G; Small C; Gu L; Haley KJ; Riese R; Ploegh HL; Chapman HA
Immunity; 1999 Feb; 10(2):197-206. PubMed ID: 10072072
[TBL] [Abstract][Full Text] [Related]
10. Proteases involved in MHC class II antigen presentation.
Villadangos JA; Bryant RA; Deussing J; Driessen C; Lennon-Duménil AM; Riese RJ; Roth W; Saftig P; Shi GP; Chapman HA; Peters C; Ploegh HL
Immunol Rev; 1999 Dec; 172():109-20. PubMed ID: 10631941
[TBL] [Abstract][Full Text] [Related]
11. Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation.
Deussing J; Roth W; Saftig P; Peters C; Ploegh HL; Villadangos JA
Proc Natl Acad Sci U S A; 1998 Apr; 95(8):4516-21. PubMed ID: 9539769
[TBL] [Abstract][Full Text] [Related]
12. Asparagine endopeptidase is not essential for class II MHC antigen presentation but is required for processing of cathepsin L in mice.
Maehr R; Hang HC; Mintern JD; Kim YM; Cuvillier A; Nishimura M; Yamada K; Shirahama-Noda K; Hara-Nishimura I; Ploegh HL
J Immunol; 2005 Jun; 174(11):7066-74. PubMed ID: 15905550
[TBL] [Abstract][Full Text] [Related]
13. Human cathepsin S, but not cathepsin L, degrades efficiently MHC class II-associated invariant chain in nonprofessional APCs.
Bania J; Gatti E; Lelouard H; David A; Cappello F; Weber E; Camosseto V; Pierre P
Proc Natl Acad Sci U S A; 2003 May; 100(11):6664-9. PubMed ID: 12748383
[TBL] [Abstract][Full Text] [Related]
14. Fc epsilon receptor I on dendritic cells delivers IgE-bound multivalent antigens into a cathepsin S-dependent pathway of MHC class II presentation.
Maurer D; Fiebiger E; Reininger B; Ebner C; Petzelbauer P; Shi GP; Chapman HA; Stingl G
J Immunol; 1998 Sep; 161(6):2731-9. PubMed ID: 9743330
[TBL] [Abstract][Full Text] [Related]
15. Early endosomal maturation of MHC class II molecules independently of cysteine proteases and H-2DM.
Villadangos JA; Driessen C; Shi GP; Chapman HA; Ploegh HL
EMBO J; 2000 Mar; 19(5):882-91. PubMed ID: 10698930
[TBL] [Abstract][Full Text] [Related]
16. Delivery of nascent MHC class II-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells.
Morton PA; Zacheis ML; Giacoletto KS; Manning JA; Schwartz BD
J Immunol; 1995 Jan; 154(1):137-50. PubMed ID: 7995933
[TBL] [Abstract][Full Text] [Related]
17. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice.
Nakagawa TY; Brissette WH; Lira PD; Griffiths RJ; Petrushova N; Stock J; McNeish JD; Eastman SE; Howard ED; Clarke SR; Rosloniec EF; Elliott EA; Rudensky AY
Immunity; 1999 Feb; 10(2):207-17. PubMed ID: 10072073
[TBL] [Abstract][Full Text] [Related]
18. The proteolytic environment involved in MHC class II-restricted antigen presentation can be modulated by the p41 form of invariant chain.
Fineschi B; Sakaguchi K; Appella E; Miller J
J Immunol; 1996 Oct; 157(8):3211-5. PubMed ID: 8871612
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of invariant chain processing, antigen-induced proliferative responses, and the development of collagen-induced arthritis and experimental autoimmune encephalomyelitis by a small molecule cysteine protease inhibitor.
Podolin PL; Bolognese BJ; Carpenter DC; Davis TG; Johanson RA; Fox JH; Long E; Dong X; Marquis RW; Locastro SM; Terfloth GJ; Kurali E; Peterson JJ; Smith BR; McQueney MS; Yamashita DS; Capper-Spudich EA
J Immunol; 2008 Jun; 180(12):7989-8003. PubMed ID: 18523262
[TBL] [Abstract][Full Text] [Related]
20. Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis.
Tolosa E; Li W; Yasuda Y; Wienhold W; Denzin LK; Lautwein A; Driessen C; Schnorrer P; Weber E; Stevanovic S; Kurek R; Melms A; Bromme D
J Clin Invest; 2003 Aug; 112(4):517-26. PubMed ID: 12925692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
